Tempest Therapeutics, Inc. (TPST) stock forecast & analysis
0.9680
NasdaqCM · USD
Up: +0.0730, +8.2%
0.9513Down: -0.0167, -1.7%
1 analysis
- Open
- 0.8500
- Previous close
- 0.8950
- Day range
- 0.8400 – 1.09
- 52-week range
- 0.7430 – 12.23
- Volume (shares)
- 4.73M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 16.54M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- -1.66
- Market cap
- 16.01M
Market Scanner’s AI analysis of Tempest Therapeutics, Inc. (TPST), updated September 2026: Tempest Therapeutics' recent analyses covered strategic licensing options, capital infusion, and mixed technical indicators.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Tempest Therapeutics, Inc. (TPST) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Tempest Therapeutics' recent analyses covered strategic licensing options, capital infusion, and mixed technical indicators.
Recent analyses for Tempest Therapeutics (TPST) examined significant strategic developments including exclusive licensing options for CAR-T platforms and a private placement raising capital. The market analyst report noted mixed short-term and long-term technical indicators, with strong recent price momentum but a significant distance from the 200-day SMA. The fundamentals analyst highlighted consistent negative operating and net income, a negative equity position, and a substantial decrease in operating income year-over-year.
TPST news & sentiment
News reports highlighted significant positive developments for Tempest Therapeutics, including strategic licensing announcements and a successful capital raise, suggesting increased investor interest and trading activity. Social media discussions were not covered in the provided notes.
TPST technical picture
Short-term price action showed strong upward momentum, trading well above the 10-day EMA and the 50-day SMA. Long-term indicators presented a bearish signal, with the price remaining significantly below the 200-day SMA. Momentum readings were above neutral but not yet overbought, while MFI suggested strong buying pressure.
Fundamentals
The company has consistently reported negative operating and net income, with operating income decreasing from 2025 to 2024 and continuing negative quarterly results in 2026. Total liabilities exceeded total assets, resulting in negative total equity and a negative Return on Equity.
Factors discussed — upside
- Exclusive option to license CD7-targeted lentiviral in vivo CAR-T platform
- Option to license new in-body CAR-T technology
- Private placement raising up to $7.5 million
- Strong short-term upward momentum indicated by price above 10-day EMA
- Medium-term trend positive as price is above 50-day SMA
Factors discussed — risks
- Price significantly below 200-day SMA
- Consistently negative operating income
- Consistently negative net income
- Negative total equity
- Negative Return on Equity (TTM)
- Strategic licensing
- Capital infusion
- Technical indicators
- Financial performance
Summary updated .
TPST technical indicators
Common technical indicators for TPST, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.99 | Price below |
| 10-day exponential moving average | 0.94 | Price above |
| Relative strength index (14-day) | 49.31 | Neutral |
| MACD line (12/26/9) | -0.0318 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 0.75 – 1.24 | Price inside the bands |
Analyses
Recent TPST.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Tempest Therapeutics, Inc.?
- The bull case for Tempest Therapeutics centers on strategic advancements, including securing exclusive options for CD7-targeted lentiviral in vivo CAR-T platforms and new in-body CAR-T technology. These developments, coupled with a successful private placement raising $7.5 million, suggest a focus on pipeline expansion and operational funding. Additionally, the company has shown strong short-term price momentum and a positive medium-term trend.
- What are the risks for Tempest Therapeutics, Inc.?
- Risks for Tempest Therapeutics include its significant distance from the 200-day SMA, indicating a bearish long-term technical signal. Fundamentally, the company has consistently reported negative operating and net income, a negative equity position, and a negative Return on Equity on a trailing twelve-month basis.
- Is Tempest Therapeutics, Inc. bullish or bearish?
- Recent AI analyses of Tempest Therapeutics, Inc. examined factors on both sides. Discussed upside: The bull case for Tempest Therapeutics centers on strategic advancements, including securing exclusive options for CD7-targeted lentiviral in vivo CAR-T platforms and new in-body CAR-T technology. These developments, coupled with a successful private placement raising $7.5 million, suggest a focus on pipeline expansion and operational funding. Additionally, the company has shown strong short-term price momentum and a positive medium-term trend. Discussed risks: Risks for Tempest Therapeutics include its significant distance from the 200-day SMA, indicating a bearish long-term technical signal. Fundamentally, the company has consistently reported negative operating and net income, a negative equity position, and a negative Return on Equity on a trailing twelve-month basis. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Tempest Therapeutics, Inc.?
- News reports highlighted significant positive developments for Tempest Therapeutics, including strategic licensing announcements and a successful capital raise, suggesting increased investor interest and trading activity. Social media discussions were not covered in the provided notes.
- How does Market Scanner analyse Tempest Therapeutics, Inc.?
- Every analysis of Tempest Therapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh TPST.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every TPST.US report already in the library